Effects of Reduced Gag Cleavage Efficiency on HIV-1 Gag-Pol Package

Yi-Ru Lin  
National Yang-Ming University: National Yang Ming Chiao Tung University

Shih-Ming Chu  
National Yang-Ming University: National Yang Ming Chiao Tung University

Fu-Hsien Yu  
National Yang-Ming University: National Yang Ming Chiao Tung University

Kuo-Jung Huang  
Taipei Veterans General Hospital

Chin-Tien Wang (✉ chintien@nycu.edu.tw)  
National Yang Ming Chiao Tung University School of Medicine  https://orcid.org/0000-0003-2231-4492

Research Article

Keywords: HIV-1, protease, Gag, Gag-Pol, Gag cleavage, virus assembly

Posted Date: February 22nd, 2022

DOI: https://doi.org/10.21203/rs.3.rs-955199/v1

License: ☛ ☑ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License

Version of Record: A version of this preprint was published at BMC Microbiology on April 9th, 2022. See the published version at https://doi.org/10.1186/s12866-022-02503-3.
Abstract

Background

HIV-1 pol, which encodes enzymes required for virus replication, is initially translated as a Gag-Pol fusion protein. Gag-Pol is incorporated into virions via interactions with Gag precursor Pr55\textsuperscript{gag}. Protease (PR) embedded in Gag-Pol mediates the proteolytic processing of both Pr55\textsuperscript{gag} and Gag-Pol during or soon after virus particle release from cells. Since efficient Gag-Pol viral incorporation depends on interaction with Pr55\textsuperscript{gag} via its N-terminal Gag domain, the prevention of premature Gag cleavage may alleviate Gag-Pol packaging deficiencies associated with cleavage enhancement from PR.

Results

We engineered PR cleavage-blocking Gag mutations with the potential to significantly reduce Gag processing efficiency. Such mutations may mitigate the negative effects of enhanced PR activation on virus assembly and Gag-Pol packaging due to an RT dimerization enhancer or leucine zipper dimerization motif. When co-expressed with Pr55\textsuperscript{gag}, we noted that enhanced PR activation resulted in reduced Gag-Pol cis or trans incorporation into Pr55\textsuperscript{gag} particles, regardless of whether or not Gag cleavage sites within Gag-Pol were blocked.

Conclusion

Our data suggest that the amount of HIV-1 Gag-Pol or Pol viral incorporation is largely dependent on virus particle production, and that cleavage blocking in the Gag-Pol N-terminal Gag domain does not exert significant impacts on Pol packaging.

Background

The HIV-1 structural protein Gag precursor Pr55\textsuperscript{gag} is capable of self-assembly into virus particles [1]. Essential viral enzymes for HIV-1 replication—including protease (PR), reverse transcriptase (RT), and integrase (IN)—are encoded by the \textit{pol} gene [2]. Pol is initially translated as a Pr160\textsuperscript{gag-pol} fusion polyprotein. Both Pr55\textsuperscript{gag} and Gag-Pol are translated from the same mRNA template. A ribosomal shift event occurs at a frequency of approximately 5% during Gag translation, resulting in a Gag-Pol/Gag expression ratio of around 1:20 [3]. It is believed that activated PR embedded in Gag-Pol mediates Pr55\textsuperscript{gag} and Gag-Pol cleavage during virus release from cell surfaces. Pr55\textsuperscript{gag} cleavage yields four major products: matrix (MA; p17), capsid (CA; p24), nucleocapsid (NC; p7) and the C-terminal p6\textsuperscript{gag} domain [4]. Within Gag-Pol, p6\textsuperscript{gag} is truncated and replaced with a transframe region labeled p6\textsuperscript{pol} or p6*. Gag-Pol cleavage yields PR, RT and IN in addition to Gag products. The PR-mediated processing of Pr55\textsuperscript{gag} and Gag-Pol (referred to as virus maturation) is necessary for acquiring viral infectivity [5–8].
By itself, Gag-Pol is incapable of budding from cells as virus-like particles (VLPs), likely due to the absence of a p6\textsuperscript{gag} budding domain [9]. Data from several studies indicate that Gag-Pol is packaged into virus particles via interaction with Pr55\textsuperscript{gag} [10–13]. PR functions as a homodimer, and interactions between Gag-Pol molecules are thought to facilitate PR activation via the promotion of PR dimerization [1]. PR overexpression from altering the Gag-Pol/Gag expression ratio is known to markedly reduce virus yields due to enhanced Pr55\textsuperscript{gag} cleavage [14, 15]. Further, increased PR or Gag-Pol dimerization can trigger premature PR activation, resulting in significantly reduced virus yields due to premature Pr55\textsuperscript{gag} cleavage prior to virus particle assembly. This idea is supported by evidence indicating that treatment with efavirenz (EFV, an RT dimerization enhancer) or the insertion of a leucine zipper dimerization motif at the PR N- or C-terminus enhances Pr55\textsuperscript{gag} cleavage efficiency, leading to substantial reductions in virus yields [16–19]. Increases in retroviral PR or Gag-Pol expression frequently result in reduced virus yields due to enhanced Gag cleavage. However, one research team has reported that avian sarcoma leukemia virus PR is expressed in a Gag-PR context at a level equivalent to that of Gag [20]. This suggests the possible involvement of unidentified factors in protease activation regulation.

PR autocleaving triggered by PR dimerization results in the release of free PR for the subsequent cleaving of Gag-Pol and Gag precursors [21]. Results from an in vitro kinetics study of HIV-1 Gag-Pol processing by PR in trans suggest that initial cleaving at p2/NC is followed by cleaving at MA/CA [22]. Other Pr55\textsuperscript{gag} cleavage studies also suggest that initial cleaving occurs between the p2 space peptide and NC protein [5, 23–28]. Cleavage occurs at the MA/CA and p1/p6 sites following initial cleavage [5, 28]. It is unknown whether PR simultaneously cleaves both Gag-Pol (cis and trans) and Pr55\textsuperscript{gag} (trans), or if PR embedded in Gag-Pol cleaves Gag-Pol before cleaving Pr55\textsuperscript{gag}. Given that both PR activation during virus assembly and Gag-Pol incorporation into virus particles are largely dependent on interactions between the Gag-Pol N-terminal Gag domain and Pr55\textsuperscript{gag}, it is likely that Gag-Pol viral incorporation decreases following the premature cleaving of Gag from Gag-Pol. To test this idea, we created several mutations to block MA/CA and p2/NC cleavage sites within Gag-Pol and/or Pr55\textsuperscript{gag}, and found that cleavage site blocking mitigated the negative impacts of enhanced PR activation on virus production. According to results from co-transfection experiments, there was no significant difference in the efficiency of Gag-Pol trans incorporation into Pr55\textsuperscript{gag} particles between wt Gag-Pol and Gag-Pol containing blocking mutations at MA/CA and p2/NC. Our data suggest that blocking Gag cleavage sites within Gag-Pol did not ameliorate the reduction in Gag-Pol packaging that resulted from enhanced Gag-Pol autocleavage, and that Gag-Pol packaging level is largely dependent on Gag virus particle production.

Results

Expression and assembly of HIV-1 Gag cleavage-deficient mutants
To test the effects of Gag cleavage on virus assembly and Gag-Pol packaging, a mutant (designated CSM) with amino acid substitution mutations was engineered to block PR cleaving at p2/NC and MA/CA (Fig. 1a). Since Gag-Pol incorporation depends on interaction with Pr55\(^{\text{gag}}\), and since Gag cleavage efficiency can affect virus particle production, we used medium-associated Gag—specifically, Gag precursor Pr55\(^{\text{gag}}\), incompletely processed p41\(^{\text{gag}}\), and/or mature p24\(^{\text{gag}}\)—as a virus production marker. Data for transient expression in 293T cells indicate significant reductions in the CSM cellular products p24\(^{\text{gag}}\) and p17\(^{\text{gag}}\) compared to those of a wt (Fig. 1b, lower panel, lane 4 vs. lane 2; supplementary Fig. 1b), confirming PR cleavage inhibition at the p2/NC and MA/CA junctions. The observation that CSM exhibited virus-associated p24\(^{\text{gag}}\) at a level comparable to that of the wt is likely due, at least in part, to western blot overexposure (Fig. 1b, middle panel, lane 4 vs. lane 2). In a repeat experiment we found that the level of CSM virus-associated p24\(^{\text{gag}}\) was noticeably lower than that of the wt (Fig. 1c, upper panel, lane 3 vs. lane 1; supplementary Fig. 1c). As a result of this blocking, substantial amounts of intermediate or incompletely processed Gag were detected in CSM supernatant and cellular samples. A band migrating slightly faster than wt p41gag (MA-CA-p2) likely corresponded to the MA-CA molecular weight (Figs. 1b and 1c, asterisks). Bands migrating to positions between Pr55gag and p41gag likely corresponded to the MA-CA-p2-NC(-p1) molecular weight (Fig. 1b, upper panel, lanes 4-5, and Fig. 1c, lanes 3-4). Some of the aberrant p24\(^{\text{gag}}\)-associated products may have resulted from cleavages at cryptic sites when MA/CA- and p2/NC-accessible sites were blocked. These partial Gag cleavage products might assemble and release as VLPs, which would be consistent with prior findings that Gag lacking p6 and/or NC domains is still capable of assembly and release as VLPs in 293T cells [34, 35].

**Effects of enhanced Gag cleavage on virus assembly and Pol packaging**

We posited that Gag-Pol dimerization facilitated by EFV might enhance Gag-Pol autocleaving, with the possibility of reduced virus-associated RT or Gag-Pol levels resulting (at least in part) from premature Gag cleavage due to the enhanced autocleaving effect. Treatment with 1 µM or 5 µM EFV was found to significantly reduce virus yields as a result of enhanced Pr55\(^{\text{gag}}\) cleavage [16, 29]. Accordingly, CSM virus particles might contain higher levels of RT or Gag-Pol when PR activation is enhanced. We treated wt and CSM transfectants with 1 µm EFV to test this possibility. Consistent with previously reported results [30], EFV treatment triggered a significant decrease in wt virus yield due to enhanced Pr55\(^{\text{gag}}\) cleavage efficiency (Figs. 1b, lane 3, 1c, lane 2 and 1d, lane 3, supplementary Figs. 1b-d). The Pr55\(^{\text{gag}}\) cleavage enhancement effect from EFV is PR activity-dependent, as evidenced by the detection of substantial amounts of Pr55\(^{\text{gag}}\) particles following treatment with an HIV-1 PR inhibitor (Fig. 1d, lane 4). In contrast, CSM virus yields were only moderately reduced following EFV treatment (Fig. 1b, lane 4 vs lane 5), suggesting that blocking PR to induce cleavages at MA/CA and p2/NC can counteract the negative EFV effect on virus production. Similar to the decrease in virus production, virus-associated RT levels also declined following EFV treatment.

**Blocking Pr55\(^{\text{gag}}\) cleavage mitigates negative impacts of Gag-Pol overexpression on virus yields and RT packaging**
Since PR can access cleavage sites on Pr55\textsuperscript{gag} and Gag-Pol, and since reduced virus yields due to enhanced Pr55\textsuperscript{gag} cleavage are frequently associated with reduced Gag-Pol packaging, it is difficult to assess the impacts of Gag cleavage inhibition on Gag-Pol packaging when both Pr55\textsuperscript{gag} and Gag-Pol are expressed from the same plasmid, as observed in the CSM case. To address this challenge, we inserted the p2/NC and MA/CA cleavage site mutations into a Gag-Pol expression vector GPfs, and co-transfected the resulting construct (designated CSMfs) with either a wt- or CSM-containing Gag expression vector (Fig. 2a). The GPfs vector contains pol and gag in the same reading frame, resulting in the expression of Pr160\textsuperscript{gag-pol} only [15]. Our data indicate that virus-associated RT, p24\textsuperscript{gag}, and p17\textsuperscript{gag} were readily detected when CSMfs or GPfs were co-transfected with a Pr55\textsuperscript{gag}-expression vector (Gag) at a DNA ratio of 1:10 (Fig. 2b, lanes 2 and 5; supplementary Fig. 2b). This suggests that Gag cleavage blocking within Gag-Pol did not exert significant impacts on the ability of Gag-Pol to be incorporated into Pr55\textsuperscript{gag} particles in trans when the Gag-Pol/Pr55\textsuperscript{gag} expression ratio was close to matching physiological conditions. Unsurprisingly, noticeable reductions in virus-associated Gag and RT resulted when a Pr55\textsuperscript{gag}-expressing vector was co-transfected with equal amounts of GPfs or CSMfs plasmid DNA (Fig. 2b lanes 3 and 6 and Fig. 2c lanes 5-6).

These data are in agreement with previously reported findings that Gag-Pol overexpression markedly reduces VLP yields. We noted that either GPfs or CSMfs overexpression with wt Gag (Pr55\textsuperscript{gag}) resulted in barely detectable virus-associated RT accompanied by a reduction in virus-associated Gag. In contrast, virus-associated RT became readily detected with increasing virus-associated Gag when GPfs or CSMfs was co-expressed with CSMGag under the same condition (Fig. 2c, lanes 8-9 vs. lanes 5-6; supplementary Fig. 2c). No Gag products were detected when GPsfs was expressed alone. However, p24\textsuperscript{gag}-associated Gag products (likely corresponding to MA-CA-p2-NC and MA-CA) were detected in CSMfs transfectant supernatants (Fig. 2c middle panel, lane 2 vs. lane 3). This suggests that blocking Gag-Pol N-terminal Gag cleavage may yield incompletely processed Gag that is capable of forming VLPs, as observed in the CSM case (Fig. 1). Similar to the Gag-Pol overexpression scenario (Fig. 2c), virus yields decreased when PR activation was enhanced via EFV treatment (Fig. 2d; supplementary Fig. 2d). However, we did not observe significant differences between GPfs and CSMfs in terms of more efficient incorporation into wt Gag or CSMGag particles.

**Effects Of Pr Activity Inhibition On Pol Packaging**

If Gag-Pol autocleaving occurs during or prior to viral incorporation, there is a possibility that PR-defective Gag-Pol may be packaged more efficiently than its PR-active counterpart. To test this possibility, PR-defective Gag-Pol with or without the CSM mutation was co-expressed with a wt. To distinguish PR-defective Gag-Pol from wt Gag-Pol, a Myc epitope was tagged at the C-terminus of PR-defective Gag-Pol and designated fsDmyc or CSMfsDmyc (Fig. 3a). Transient co-expression results indicate that increases in co-transfected amounts of these PR-defective Gag-Pol expression vectors led to increases in Gag and Gag-Pol precursors associated with moderate decreases of RT66/51 and integrase (IN) in supernatant...
samples (Figs. 3b-c, lanes 3-6, and Figs. 3d-e, lanes 3-8; supplementary Figs. 3b-e). These findings suggest that due to overexpression, PR-defective Gag-Pol is packaged at a higher frequency than wt Gag-Pol, and that the defective PR domain interferes with wt PR activity, resulting in the inefficient processing of Pr55\textit{gag} and Gag-Pol. Virus-associated IN and IN-myc levels were roughly equal when co-transfected PR-defective Gag-Pol plasmids were reduced to near-wt Gag-Pol expression levels (Fig. 3c, lanes 3 and 5). Combined, these data suggest that wt Gag-Pol is capable of mediating the processing of incorporated PR-defective Gag-Pol in trans, and that PR-defective Gag-Pol (with or without CSM) does not exhibit greater packaging efficiency compared to wt Gag-Pol when the two are co-expressed at approximately equal levels.

**Effects Of Enhanced Gag-pol Autocleavage On Pol Packaging**

In a previous report we described a Dp6*PR construct containing a duplicate p6*-PR with an inactivated proximal PR copy exhibiting a wt virus processing profile [31]. However, in that study virus-associated Gag was barely detectable when a leucine zipper (LZ) dimerization motif was substituted for the p6* and placed adjacent to the active PR. The severe assembly defect of this mutant (designated DWzPR) resulted from enhanced PR activation due to an LZ substitution for the deleted p6*, but a DWz/PR construct containing four C-terminal p6* residues in the deleted p6* region was found to counteract the LZ enhancement of PR activation [19]. We hypothesized that enhanced Gag-Pol autocleavage triggered by LZ may lead to reduced Pol viral incorporation, and that preventing Gag cleavage from Gag-Pol might retain that incorporation at the same level.

To test this possibility, a CSM mutation was cloned into DWzPR and DWz/PR, respectively yielding CSM/DWzPR and CSM/DWz/PR (Fig. 4a). Transient expression results indicate that DWzPR produced barely detectable virus-associated Gag, while DWz/PR virus-associated Gag products were readily detectable (Fig. 4b; supplementary Fig. 4b); this is consistent with previous reports [19, 32]. We found that compared to the wt transfectant, cellular Pr55\textit{gag} was barely detectable in DWzPR and DWz/PR transfectants (Fig. 4b lower panel, lanes 2-4), indicating enhanced PR-mediated Gag cleavage efficiency. Both DWzPR and DWz/PR exhibited barely detectable or noticeably reduced virus-associated RT compared to their CSM-containing counterparts (Fig. 4b upper panel, lanes 3-4 vs. lanes 6-7, and Fig. 4c).

The results shown in Figure 4 suggest that blocking Gag cleavage can partly counteract the reduced Pol packaging incurred by the LZ replacement of p6*. However, Pol or Gag-Pol packaging is primarily determined by their respective ability to associate with Pr55\textit{gag}. In addition to reducing VLPs, enhanced PR activation may reduce Gag-Pol viral packaging as a result of enhanced Gag-Pol autocleavage. Since it is difficult to assess the impact of enhanced Gag-Pol autocleavage incurred by LZ on Gag-Pol packaging when Gag cleavage sites within Pr55\textit{gag} and Gag-Pol are blocked, we assessed the degree of DWZPR and DWz/PR Gag-Pol incorporation into wt Pr55\textit{gag} particles. After cloning DWzPR and DWz/PR with or without the CSM mutation into the GPfs backbone (Fig. 5a), each resultant construct was co-transfected
with the Pr55<sup>gag</sup> expression vector. Our results indicate that the leucine zipper replacement of p6* significantly reduced RT-associated products in virus particles (Fig. 5b upper panel, lanes 3-4 and 6-7 and Fig. 5d; supplementary Fig. 5b). However, virus-associated RT levels in DWzPRfs and DWz/PRfs did not increase significantly when Gag cleavage sites were blocked (Fig. 5b lane 3 vs. lane 6 and lane 4 vs. lane 7; Fig. 5d). As an additional test, Pr55<sup>gag</sup> was co-expressed with a W420A-containing GPfs construct with or without the CSM mutation. W402A (with an alanine substitution of the RT codon W402) was found to be severely assembly-defective due to enhanced PR activation triggered by the W402A mutation [33]. Consistent with Chiang et al.'s results, W402A exhibited markedly reduced VLP yields compared to the wt (Fig. 5c, lanes 2-3; supplementary Fig. 5c) and reduced Pol incorporation into Pr55<sup>gag</sup> particles, regardless of whether or not the Gag-Pol contained CSM (Fig. 5c upper panel, lanes 5-8).

**Discussion**

We found that amino acid substitutions at the MA/CA and p2/NC junctions significantly reduced Gag cleavage efficiency. We also noted readily detected virus-associated p66/51RT expressed by CSM, suggesting that Gag cleavage site blocking did not exert major impacts on PR cleaving at Pol substrate sites (Fig. 1). Gag-Pol viral incorporation depends on interaction with Pr55gag. Although partial Pr55<sup>gag</sup> cleavage products are VLP assembly-competent, they are likely defective in their interactions with Gag-Pol, resulting in RT-deficient VLP assembly. This may have contributed, at least in part, to the significant reduction observed in CSM virus-associated RT compared to the wt (Fig. 1 and Fig. 4).

The results shown in Figure 2C suggest that blocking Gag cleavage could alleviate the negative impact of Gag-Pol overexpression on virus particle production and Pol packaging, whether or not the Gag-Pol contained the CSM mutation. Likewise, we observed that enhanced Gag-Pol autocleaving by EFV resulted in lower VLP yields associated with reduced Pol (RT) incorporation (Fig. 2d), regardless of the presence or absence of the CSM mutation. Similarly, enhanced Gag-Pol autocleavage triggered by the LZ replacement of p6* led to significantly reduced Pol packaging efficiency, regardless of whether or not the Gag-Pol domain contained cleavage site mutations at MA/CA and p2/NC. (Fig. 5). These findings suggest that the degree of Gag-Pol incorporation into VLPs is largely determined by the level of Gag particle production, regardless of the presence or absence of CSM. Our results indicate enhanced Gag-Pol autocleaving following Gag-Pol over-expression, EFV treatment, the replacement of p6* with LZ, or an alanine substitution for W402, resulting in reduced virus-associated Gag and RT levels. The observation that enhanced PR activation led to significant and simultaneous reductions in VLP yields and Pol packaging suggests that PR, once activated, can immediately mediate Gag-Pol and Gag processing during virus assembly. Enhanced or premature Gag-Pol autocleavage may impede Gag-Pol viral incorporation, which in turn might partly account for the observed significant reduction in DWz/PR virus-associated RT (Fig. 4).

**Conclusion**
Our results suggest that Gag cleavage blocking can mitigate the negative effect of enhanced PR-mediated Gag cleavage efficiency, thereby moderating Pol packaging linked with reduced virus yields. Enhanced Gag-Pol autocleavage or degradation due to premature or enhanced PR activation may explain, at least in part, the observed reduction in Pol packaging efficiency. However, cleavage blocking at MA/CA or p2/NC within Gag-Pol did not significantly mitigate the Pol packaging defect incurred by enhanced Gag-Pol autocleavage.

Methods

Plasmid construction. The parental HIV-1 proviral sequence in this study is HXB2 [36]. CSM was constructed via the recombination of two mutants, MA/CA and p2/NC, both of which contain alanine substitutions for PR substrate residues at the MA/CA (Tyr/Pro) and p2/NC (Met/Met) junctions. Alanine substitutions for Tyr/Pro at the MA/CA cleavage site were executed by megaprimer PCR [37] using a mutation-containing forward primer 5’-CAGGTCAGCCAAAATGCCGCTATTGTACAGAACAT-3’, a downstream reverse primer 5’-TTGGACCAACAAGGTTTCTGTC-3’ (nt. 1761-39), and an upstream forward primer 5’-GACTAGCGAGGCTAGAAG-3’ (nt. 763-81). HIVgpt [38] served as a template. PCR-amplified fragments were digested with Clal and Spel and cloned into HIVgpt. Similarly, a p2/NC cleavage site mutation was created using a mutation-containing forward primer 5’-AACAAATTCAGCTACGATCGCTGCTAGAGAGGCA-3’, a downstream reverse primer 5’-GGTAGCTACGCTAGCTGCTAGAGAGGCA-3’, a downstream reverse primer 5’-GGTACAGTCTCAATAGGGCTAATG-3’ (nt. 2577-51), and an upstream forward primer 5’-GGACTACTAGTACCCTCCAGGAACATG-3’ (nt. 1500-27). Amplified fragments were digested with Spel and BclI prior to ligation into HIVgpt. As previously described, GPfs contains Gag and Pol in the same reading frame due to a frameshift signal deletion [15]. Construct fsD is a PR-inactivated version of GPfs [15]. fsDmyc was created by the in-frame fusing of the myc-his tag coding sequence (Xhol-Pmel fragment from pcDNA3.1/myc-His A) to fsDSal containing a SalI site at the IN C-terminus. The recombination of fsDmyc and CSM generated CSMfsDmyc. DWzPR and DWz/PR were as previously described [19]. CSM recombined with DWzPR and DWz/PR yielded CSM/DWzPR and CSM/DWz/PR, respectively. All constructs located in the HIVgpt backbone [38] were confirmed by enzyme digestion or sequencing.

Cell culture and transfection. 293T cells were maintained in DMEM supplemented with 10% fetal calf serum. Confluent 293T cells were trypsinized, split 1:10, and seeded onto 10 cm plates 18-24 h prior to transfection. For each construct, 293T cells were transfected with 20 µg of plasmid DNA by calcium phosphate precipitation, with the addition of 50 µM chloroquine to enhance transfection efficiency. Culture medium and cells were harvested for protein analysis at 48-72 h post-transfection. When co-transfecting Pr55gag-expressing plasmids with Gag-Pol expression constructs at DNA ratios of 1:1 or 10:1, pBlueScript (SK) plasmid DNA was added to 10 or 15 µg of pGag to a final quantity of 20 µg.

Western immunoblot analysis. Culture medium from transfected 293T cells were filtered (0.45 µm pore size) and centrifuged through 2 ml 20% sucrose in TSE (10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA) containing 0.1 mM phenylmethylsulfonyl fluoride (PMSF) at 4°C for 40 min at 274,000 × g. Next, viral pellets and cell lysates mixed with sample buffer were subjected to SDS 10% PAGE with 4-12% Bis-
Tris gradient gels (NuPage Bis-Tris Mini Gels; Thermo Fisher Scientific), followed by immunoblotting as previously described [30]. HIV-1 Gag proteins were probed with anti-p24gag (mouse hybridoma clone 183-H12-5C) and/or anti-p17gag (No. HB-8975; American Type Culture Collection, Rockville, MD) monoclonal antibodies from ascites. Rabbit antiserum or mouse anti-RT monoclonal antibodies served as primary antibodies for HIV-1 RT detection [39, 40]. Cellular b-actin was detected using a mouse anti-b-actin monoclonal antibody (Sigma) with either a sheep anti-mouse or a donkey anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (Jackson ImmunoResearch). Membrane-bound protein detection was performed using an enhanced chemiluminescent substrate (SuperSignal West Pico; Thermo Fisher Scientific).

**Declarations**

**Ethics approval and consent to participate**: Not applicable.

**Consent to publish**: All authors contributed critically to the drafts and gave final approval for publication.

**Availability of data and materials**: The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

**Competing interests**: The authors declare that they have no competing interests.

**Funding** This research was supported by grants from Taipei Veterans General Hospital (V106C-047, V107C-049 and V108C-034) and the Taiwan Ministry of Science and Technology (106-2320-B-010-017-MY2 and 108-2320-B-010-030). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Authors’ contributions**

Y-RL and S-MC designed the experiments. F-HY and K-JH performed the experiments and analyzed the data. C-TW wrote the manuscript.

**Acknowledgements**

We KT Lee for reagent preparation and technical assistance.

**References**

1. Freed EO. HIV-1 assembly, release and maturation. Nat Rev Microbiol. 2015;13:484.
2. Petropoulos C. Retroviral Taxonomy, Protein Structures, Sequences, and Genetic Maps. In: Retroviruses. Edited by Coffin JM, Hughes SH, Varmus HE. Cold Spring Harbor Laboratory Press; 1997.
3. Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature. 1988;331(6153):280–3.
4. Swanstrom R, Wills JW. Synthesis, Assembly, and Processing of Viral Proteins. In: Retroviruses. Edited by Coffin JM, Hughes SH, Varmus HE. Cold Spring Harbor Laboratory Press; 1997.

5. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein CA, et al. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol. 1994;68(12):8017–27.

6. Gottlinger HG, Sodroski JG, Haseltine WA. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1989;86(15):5781–5.

7. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A. 1988;85(13):4686–90.

8. Peng C, Ho BK, Chang TW, Chang NT. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol. 1989;63(6):2550–6.

9. Guo TW, Yu FH, Huang KJ, Wang CT. p6gag domain confers cis HIV-1 Gag-Pol assembly and release capability. J Gen Virol. 2016;97(1):209–19.

10. Smith AJ, Srinivasakumar N, Hammarskjöld ML, Rekosh D. Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles. J Virol. 1993;67(4):2266–75.

11. Srinivasakumar N, Hammarskjöld ML, Rekosh D. Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag-Pol precursor incorporation. J Virol. 1995;69(10):6106–14.

12. Huang M, Martin MA. Incorporation of Pr160(gag-pol) into virus particles requires the presence of both the major homology region and adjacent C-terminal capsid sequences within the Gag-Pol polyprotein. J Virol. 1997;71(6):4472–8.

13. Park J, Morrow CD. The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into virusslike particles. J Virol. 1992;66(11):6304–13.

14. Shehu-Xhilaga M, Crowe SM, Mak J. Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity. J Virol. 2001;75(4):1834–41.

15. Chiu HC, Yao SY, Wang CT. Coding sequences upstream of the human immunodeficiency virus type 1 reverse transcriptase domain in gag-pol are not essential for incorporation of the pr160gag-pol into virus particles. J Virol. 2002;76(7):3221–31.

16. Figueiredo A, Moore KL, Mak J, Sluis-Cremer N, de Bethune MP, Tachedjian G. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog. 2006;2(11):e119.

17. Tachedjian G, Orlova M, Sarafianos SG, Arnold E, Goff SP. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci U S A. 2001;98(13):7188–93.
18. Pan YY, Wang SM, Huang KJ, Chiang CC, Wang CT. Placement of leucine zipper motifs at the carboxyl terminus of HIV-1 protease significantly reduces virion production. Plos One. 2012;7(3):e32845.

19. Yu FH, Huang KJ, Wang CT. C-terminal HIV-1 transframe p6* tetrapeptide blocks enhanced gag cleavage incurred by leucine zipper replacement of a deleted p6* domain. J Virol. 2017;91(10).

20. Konvalinka J, Kräusslich H-G, Müller B. Retroviral proteases and their roles in virion maturation. Virology. 2015;479-480:403–17.

21. Huang L, Chen C. Understanding HIV-1 protease autoprocessing for novel therapeutic development. Future Med Chem. 2013;5(11):1215–29.

22. Pettit SC, Lindquist JN, Kaplan AH, Swanstrom R. Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology. 2005;2(1):66.

23. Erickson-Viitanen S, Manfredi J, Viitanen P, Tribe De, Tritch R, Clyde A. Hutchison I, et al. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retrovir. 1989;5(6):577–91.

24. Gowda SD, Stein BS, Engleman EG. Identification of protein intermediates in the processing of the p55 HIV-1 gag precursor in cells infected with recombinant vaccinia virus. J Biol Chem. 1989;264(15):8459–62.

25. Kräusslich HG, Ingraham RH, Skoog MT, Wimmer E, Pallai PV, Carter CA. Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc Natl Acad Sci U S A. 1989;86(3):807–11.

26. Mervis RJ, Ahmad N, Lillehoj EP, Raum MG, Salazar FH, Chan HW, et al. The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors. J Virol. 1988;62(11):3993–4002.

27. Pettit SC, Henderson GJ, Schiffer CA, Swanstrom R. Replacement of the P1 amino acid of human immunodeficiency virus type 1 gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol. 2002;76(20):10226–33.

28. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Kräusslich HG. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual gag polyprotein cleavage sites. J Virol. 1998;72(4):2846–54.

29. Chiang CC, Tseng YT, Huang KJ, Pan YY, Wang CT. Mutations in the HIV-1 reverse transcriptase tryptophan repeat motif affect virion maturation and Gag-Pol packaging. Virology. 2012;422(2):278–87.

30. Chiang CC, Wang SM, Tseng YT, Huang KJ, Wang CT. Mutations at human immunodeficiency virus type 1 reverse transcriptase tryptophan repeat motif attenuate the inhibitory effect of efavirenz on virus production. Virology. 2009;383(2):261–70.
31. Yu FH, Chou TA, Liao WH, Huang KJ, Wang CT. Gag-Pol Transframe Domain p6* Is Essential for HIV-1 Protease-Mediated Virus Maturation. PLoS One. 2015;10(6):e0127974.

32. Yu FH, Wang CT. HIV-1 protease with leucine zipper fused at N-terminus exhibits enhanced linker amino acid-dependent activity. Retrovirology. 2018;15(1):32.

33. Chiang CC, Wang SM, Pan YY, Huang KJ, Wang CT. A single amino acid substitution in HIV-1 reverse transcriptase significantly reduces virion release. J Virol. 2010;84(2):976–82.

34. Wang CT, Lai HY, Li JJ. Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release. J Virol. 1998;72(10):7950–9.

35. Liao WH, Huang KJ, Chang YF, Wang SM, Tseng YT, Chiang CC, et al. Incorporation of human immunodeficiency virus type 1 reverse transcriptase into virus-like particles. J Virol. 2007;81(10):5155–65.

36. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature. 1985;313(6000):277–84.

37. Boles E, Miosga T. A rapid and highly efficient method for PCR-based site-directed mutagenesis using only one new primer. Curr Genom. 1995;28(2):197–8.

38. Page KA, Landau NR, Littman DR. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol. 1990;64(11):5270–6.

39. Ferris AL, Hizi A, Showalter SD, Pichuantes S, Babe L, Craik CS, et al. Immunologic and proteolytic analysis of HIV-1 reverse transcriptase structure. Virology. 1990;175(2):456–64.

40. Hizi A, McGill C, Hughes SH. Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc Natl Acad Sci U S A. 1988;85(4):1218–22.

Figures
**Figure 1**

**Effects of Gag cleavage site mutations on virus assembly and processing.** (a) Schematic representations of HIV-1 Gag and Gag-Pol expression constructs. Indicated are the HIV-1 Gag protein domains MA (matrix), CA (capsid), p2, NC (nucleocapsid), p1 and p6, and pol-encoded p6*, PR, RT and IN. Arrowheads indicate where alanines (A/A) were substituted for amino acid residues at the MA/CA (Y/P) and p2/NC (M/M) junctions. (b-d) Enhanced PR activation by efavirenz (EFV) reduced virus yields and Gag-Pol
packaging. 293T cells were transfected with designated constructs. At 18 h post-transfection, transfectants were equally split, placed on two plates, and either treated or mock-treated with 1 μM EFV. At 4 h post-treatment, culture supernatants were removed and replaced with medium containing EFV with or without an HIV-1 protease inhibitor (panel d). Cells and supernatants were harvested for Western immunoblot analysis 48 h after medium replacement. HIV-1 Gag proteins were probed with anti-p24CA and anti-p17MA monoclonal antibodies. Anti-RT serum was used to detect RT. Indicated are positions of the RT p66 and p51 subunits, Pr55<sup>gag</sup>, p4<sup>1gag</sup>, p24<sup>gag</sup> and p17<sup>gag</sup>.

Figure 2

(a) Schematic representations of HIV-1 Gag and Gag-Pol expression constructs. Gag domains, pol-encoded products, and protease cleavage sites are indicated. (b) Western immunoblots showing Gag and Pol proteins in medium and cell lysates from cells expressing wild-type or mutant Gag constructs. (c) Effects of Gag cleavage mutation on Gag-Pol trans incorporation into virus particles. (d) Effects of HIV-1 protease inhibitor on Gag-Pol trans incorporation into virus particles.
and Gag cleavage site mutations are identical to those described in the Figure 1 caption. GPfs and CSMfs both contained the same gag/pol frameshifting mutation to force Gag-Pol expression without Gag. (b) 293T cells were transfected with indicated amounts of GPfs or CSMfs plasmid DNA, either alone or with 10 µg Gag plasmid DNA at a ratio of 1:10 (lanes 2 and 5) or 1:1 (lanes 3 and 6). (c) 293T cells were transfected with 10 µg GPfs or CSMfs plasmid DNA, either alone or with 10 µg Gag (lanes 5-6) or CSMGag (lanes 8-9) plasmid DNA. Ten µg of pBluescript (SK) plasmid DNA was added to give a total of 20 µg DNA for each transfection. (d) 293T cells were co-transfected with either Gag (10 µg) or CSMGag (10 µg) plus either GPfs (1 µg) or CSMfs (1 µg) expression vectors. At 18 h post-transfection, transfectants were equally split, placed on two plates, and either treated or mock-treated with 1 µM efavirenz (EFV). After an additional 4 h (22 h post-transfection), culture supernatants were removed and replaced with medium containing EFV. Cells and supernatants were harvested for Western immunoblot analysis 48 h post-medium replacement.
Figure 3

Incorporation of PR-defective Gag-Pol into wt virus particles. (a) Schematic representations of HIV-1 Gag and Gag-Pol expression vectors. Indicated are the HIV-1 Gag protein domains MA (matrix), CA (capsid), p2, NC (nucleocapsid), p1 and p6, and pol-encoded p6*, PR, RT and IN, all as described in the Figure 1 caption. "X" denotes a substitution mutation at the PR catalytic Asp residue. The C-termini of constructs fsDmyc and CSMfsDmyc are attached with myc epitopes. (b-e) 293T cells were transfected with 10 μg of
wt plasmid DNA plus the indicated amounts of fsDmyc or CSMfsDmyc plasmid DNA. At 48 h post-transfection, cells and supernatants were collected, prepared, and subjected to Western immunoblotting. Gag proteins were probed with anti-p24CA and anti-p17MA monoclonal antibodies. Panel c was derived from panel b following sequential probing with anti-RT, anti-Myc or anti-IN antibodies.

**Figure 4**

(a) Diagram showing protein domains and insertions in different constructs.

(b) Western blot images of media and cell lysates for different constructs.

(c) Bar graph showing relative virus-associated RT levels for different constructs.
Virus yields and Gag-Pol packaging reduced by enhanced Gag-Pol autocleavage. (a) Schematic representations of HIV-1 Gag and Gag-Pol expression constructs. “X” denotes a PR-inactivated mutation. p6* adjacent to the active PR domain was replaced with a leucine zipper (LZ) as denoted by the striped (Wz) box. Remaining C-terminal p6* residues are in boldface. Arrows denote PR cleavage sites. Altered or additional residues are in italics. (b) 293T cells were transfected with designated constructs. Two days post-transfection, cells and supernatants were collected, prepared, and subjected to Western immunoblotting. (c) Relative levels of virus-associated RT. Levels of HIV-1 p24gag-associated Gag proteins Pr55, p41, and p24 and RT-associated Pol proteins Gag-Pol, Pol and p66/51RT were quantified by scanning immunoblot band densities. Ratios of total virus-associated RT versus Gag protein levels were calculated for each sample and normalized to the wt in parallel experiments. All data were obtained from three independent experiments. Error bars indicate standard deviation. *p<0.05.
Enhanced Gag-Pol autocleavage reduced Gag-Pol trans incorporation into Gag particles. (a) Schematic representations of HIV-1 Gag and Gag-Pol expression constructs. Designated constructs are identical to those shown in Figure 4a, but expressed in a gag/pol frameshift mutation backbone (GPfs). (b-c) 293T cells were transfected with WT or W402A or co-transfected with the designated construct plus a Pr55gag (Gag) expression vector at a plasmid DNA ratio of 1:10. SK denotes the plasmid pBluescript. At 48-72 h...
post-transfection, cells and supernatants were collected, prepared, and subjected to Western immunoblotting. Relative levels of virus-associated RT are indicated at bottom. (d) Relative levels of virus-associated RT were determined as described in the Figure 4 caption. All data are from three independent experiments. Error bars indicate standard deviation. *p<0.05.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- OriginaluncroppedblotFig1B.jpg
- OriginaluncroppedblotFig1C.jpg
- OriginaluncroppedblotFig1D.jpg
- OriginaluncroppedblotFig2B.jpg
- OriginaluncroppedblotFig2C.jpg
- OriginaluncroppedblotFig2D.jpg
- OriginaluncroppedblotFig3B.jpg
- OriginaluncroppedblotFig3C.jpg
- OriginaluncroppedblotFig3D.jpg
- OriginaluncroppedblotFig3E.jpg
- OriginaluncroppedblotFig4B.jpg
- OriginaluncroppedblotFig5B.jpg
- OriginaluncroppedblotFig5C.jpg